Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors

References

• Cuny GD, Degterev A. RIPK protein kinase family: atypical lives of typical kinases. Semin Cell Dev Biol 2021;109:96–105.
   PubMed Web of Science ®Google Scholar
• Trindade BC, Chen GY. NOD1 and NOD2 in inflammatory and infectious diseases. Immunol Rev 2020;297(1):139–161.
   PubMed Web of Science ®Google Scholar
• Pellegrini E, Desfosses A, Wallmann A, et al. RIP2 filament formation is required for NOD2 dependent NF-κB signalling. Nat Commun 2018;9(1):4043.
   PubMedGoogle Scholar
• Hrdinka M, Schlicher L, Dai B, et al. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. Embo J. 2018;37(17):e99372.
   PubMed Web of Science ®Google Scholar
• Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003;4(7):702–707.
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Viala J, et al. NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278(11):8869–8872.
   PubMed Web of Science ®Google Scholar
• Witt A, Vucic D. Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling. Cell Death Differ. 2017;24(7):1160–1171.
   PubMed Web of Science ®Google Scholar
• Tigno-Aranjuez JT, Asara JM, Abbott DW. Inhibition of RIP2’s tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev. 2010;24(23):2666–2677.
   PubMed Web of Science ®Google Scholar
• Goncharov T, Hedayati S, Mulvihill MM, et al. Disruption of XIAP-RIP2 association blocks NOD2-mediated inflammatory signaling. Mol Cell. 2018;69(4):551–565.e7.
   PubMed Web of Science ®Google Scholar
• Nachbur U, Stafford CA, Bankovacki A, et al. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nat Commun. 2015;6(1):6442.
   PubMedGoogle Scholar
• Speir M, Djajawi TM, Conos SA, et al. Targeting RIP kinases in chronic inflammatory disease. Biomolecules. 2021;11(5):646.
   PubMed Web of Science ®Google Scholar
• He S, Wang X. RIP kinases as modulators of inflammation and immunity. Nat Immunol. 2018;19(9):912–922.
   PubMed Web of Science ®Google Scholar
• Marinis JM, Homer CR, McDonald C, Abbott DW. A novel motif in the Crohn’s disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses. J Biol Chem. 2011;286(3):1938–1950.
   PubMed Web of Science ®Google Scholar
• Argast GM, Fausto N, Campbell JS. Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. Mol Cell Biochem. 2005;268(1–2):129–140.
   PubMed Web of Science ®Google Scholar
• Tigno-Aranjuez JT, Benderitter P, et al. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J Biol Chem. 2014;289(43):29651–29664.
   PubMed Web of Science ®Google Scholar
• Canning P, Ruan Q, Schwerd T, et al. Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type ii kinase inhibitors. Chem Biol. 2015;22(9):1174–1184.
   PubMedGoogle Scholar
• Yuan X, Chen Y, Tang M, et al. Discovery of potent and selective receptor-interacting serine/threonine protein kinase 2 (RIPK2) inhibitors for the treatment of inflammatory bowel diseases (IBDS). J Med Chem. 2022;65(13):9312–9327.
   PubMed Web of Science ®Google Scholar
• Suebsuwong C, Dai B, Pinkas DM, et al. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. Eur J Med Chem. 2020;200:112417.
   PubMed Web of Science ®Google Scholar
• Haffner CD, Charnley AK, Aquino CJ, et al. Discovery of pyrazolocarboxamides as potent and selective receptor interacting protein 2 (RIP2) kinase inhibitors. ACS Med Chem Lett. 2019;10(11):1518–1523.
   PubMed Web of Science ®Google Scholar
• Salla M, Aguayo-Ortiz R, Danmaliki GI, et al. Identification and characterization of novel receptor-interacting serine/threonine‐protein kinase 2 inhibitors using structural similarity analysis. J Pharmacol Exp Ther. 2018;365(2):354–367.
   PubMed Web of Science ®Google Scholar
• He X, Da Ros S, Nelson J, et al. Identification of potent and selective RIPK2 inhibitors for the treatment of inflammatory diseases. ACS Med Chem Lett. 2017;8(10):1048–1053.
   PubMed Web of Science ®Google Scholar
• Haile PA, Casillas LN, Votta BJ, et al. Discovery of a first-in-class receptor interacting protein 2 (RIP2) kinase specific clinical candidate, 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate, for the treatment of inflammatory diseases. J Med Chem. 2019;62(14):6482–6494.
   PubMed Web of Science ®Google Scholar
• Haile PA, Votta BJ, Marquis RW, et al. The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-n-(5-fluoro-1h-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase. J Med Chem. 2016;59(10):4867–4880.
   PubMed Web of Science ®Google Scholar
• Gilday LC, Robinson SW, Barendt TA, et al. Halogen bonding in supramolecular chemistry. Chem Rev. 2015;115(15):7118–7195.
   PubMed Web of Science ®Google Scholar
• Eid S, Turk S, Volkamer A, et al. Kinmap: a web-based tool for interactive navigation through human kinome data. BMC Bioinformatics. 2017;18(1):16.
   PubMedGoogle Scholar